Dimension Therapeutics (DMTX) Given Coverage Optimism Score of 0.27

News headlines about Dimension Therapeutics (NASDAQ:DMTX) have been trending positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dimension Therapeutics earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.1161018949312 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Dimension Therapeutics (NASDAQ DMTX) traded down $0.03 on Monday, hitting $5.95. 27,700 shares of the stock traded hands, compared to its average volume of 150,214. The company has a market cap of $149.06 and a PE ratio of -2.67. Dimension Therapeutics has a one year low of $1.05 and a one year high of $6.10. The company has a quick ratio of 3.33, a current ratio of 2.01 and a debt-to-equity ratio of 0.14.

Dimension Therapeutics (NASDAQ:DMTX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.20). The business had revenue of $4.48 million for the quarter. Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. equities research analysts forecast that Dimension Therapeutics will post -1.99 EPS for the current year.

Several analysts have commented on the stock. Citigroup upgraded shares of Dimension Therapeutics from a “sell” rating to a “neutral” rating and raised their target price for the stock from $5.50 to $6.00 in a report on Tuesday, October 3rd. Chardan Capital restated a “buy” rating on shares of Dimension Therapeutics in a report on Friday, December 22nd. Wells Fargo & Co downgraded shares of Dimension Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $9.00 to $6.00 in a report on Tuesday, October 3rd. Finally, ValuEngine upgraded shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 30th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. Dimension Therapeutics presently has a consensus rating of “Hold” and an average price target of $5.08.

COPYRIGHT VIOLATION WARNING: “Dimension Therapeutics (DMTX) Given Coverage Optimism Score of 0.27” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://sportsperspectives.com/2018/01/08/dimension-therapeutics-dmtx-given-coverage-optimism-score-of-0-27.html.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Insider Buying and Selling by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply